This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
NDRA's TAEUS Device Achieves MRI-Level Liver Imaging Precision
by Zacks Equity Research
ENDRA posts strong TAEUS Liver study data, showing high measurement reliability for MASLD monitoring and boosting its regulatory and commercial outlook.
PHGNegative Net Change MDTNegative Net Change NDRANegative Net Change GEHCNegative Net Change
medical medical-devices
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub
by Zacks Equity Research
PACB teams with DNAstack to launch a global HiFi genome network, linking 10,000+ sequences to boost rare disease research without moving data.
TMONegative Net Change ILMNNegative Net Change PACBNegative Net Change TXGNegative Net Change
medical medical-devices
After Golden Cross, Central Garden (CENTA)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CENTANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Global Industrial (GIC)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
GICNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Central Garden (CENT) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CENTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Medtronic Debuts MiniMed Go Smart MDI With Simplera Sensor in Europe
by Zacks Equity Research
MDT launches MiniMed Go Smart MDI with the Simplera sensor in Europe, advancing connected insulin care as the Diabetes unit's IPO plans progress.
ABTNegative Net Change MDTNegative Net Change PODDNegative Net Change TNDMNegative Net Change
medical medical-devices
Can Digital Subscriptions Become ISRG's New Revenue Stream in 2026?
by Indrajit Bandyopadhyay
Intuitive Surgical's My Intuitive+ may turn paid in 2026, adding a software-driven revenue layer as renewals begin and digital engagement scales.
ISRGPositive Net Change STXSNegative Net Change GMEDNegative Net Change
medical medical-devices
Is the Options Market Predicting a Spike in Humana Stock?
by Zacks Equity Research
Investors need to pay close attention to Humana stock based on the movements in the options market lately.
HUMNegative Net Change
medical medical-devices
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis
by Zacks Equity Research
Organon reports Phase 3 data showing VTAMA improved sleep in children as young as two with atopic dermatitis, reinforcing its dermatology push.
ISRGPositive Net Change CAHNegative Net Change VCYTNegative Net Change OGNNegative Net Change
medical medical-devices
Can AI Acceleration and R&D Strength Drive VEEV Ahead of Q4 Earnings?
by Zacks Equity Research
Veeva Systems Q4 earnings are likely to benefit from Vault CRM migration, AI rollout and R&D strength.
CRMPositive Net Change VEEVPositive Net Change IQVNegative Net Change SDGRPositive Net Change
medical medical-devices